Investor directory

Recombinetics

Recombinetics is a developer of gene editing technologies to improve human health through advanced disease models and regenerative medicine. Its gene-editing technologies manipulate deoxyribonucleic acid (DNA) samples to add and activate genes to solve problems and also offer gene repair and gene editing tools that enable biomedical research, livestock productivity, animal agriculture, and livestock vertical markets to modify animal genomes accurately and efficiently.

Top Stages

Acquisition
http://recombinetics.com
https://crunchbase.com/organization/recombinetics
https://facebook.com/recombineticsinc
https://linkedin.com/company/recombinetics-inc.
https://pitchbook.com/profiles/company/55988-74
https://twitter.com/recombinetics
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=213659347

1 past transactions

Makana Therapeutics

Acquisition in 2020
Makana Therapeutics is focused on developing swine with reduced xenoantigen expression, making human transplantation of cells, tissues and organs from these animals possible. Makana’s focus on simplified genetics, optimized pig cloning techniques, and careful patient selection is expected to streamline product development and result in safer more efficacious products. It was founded in 2009 and is based in Miami, Florida, United States.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.